Trial record 1 of 4 for:    "cerebrotendinous xanthomatosis"
Previous Study | Return to List | Next Study

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2003 by National Center for Research Resources (NCRR).
Recruitment status was  Recruiting
Oregon Health and Science University
Information provided by:
National Center for Research Resources (NCRR) Identifier:
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: December 2003

OBJECTIVES: I. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in patients with cerebrotendinous xanthomatosis before and after a cholesterol- and cholestanol-free diet.

II. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in these patients before and after lovastatin and chenodeoxycholic acid.

Condition Intervention Phase
Cerebrotendinous Xanthomatosis
Drug: chenodeoxycholic acid
Drug: lovastatin
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)

Resource links provided by NLM:

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment: 5
Study Start Date: January 1996
Detailed Description:

PROTOCOL OUTLINE: Following a 2-week baseline assessment, patients participate in a feeding study for up to 3 weeks. The diet is free of cholesterol and cholestanol.

For the next 4 weeks, patients return to their typical diet and are medicated with daily lovastatin and chenodeoxycholic acid.

The feeding study is repeated for an additional 3 weeks, with the patient taking either lovastatin or chenodeoxycholic acid.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

PROTOCOL ENTRY CRITERIA: Cerebrotendinous xanthomatosis

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004346

United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239-3098
Contact: Sonja Connor    503-494-7775   
Sponsors and Collaborators
Oregon Health and Science University
Study Chair: William Connor Oregon Health and Science University
  More Information

No publications provided Identifier: NCT00004346     History of Changes
Other Study ID Numbers: NCRR-M01RR00334-0067, OHSU-4008
Study First Received: October 18, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
cerebrotendinous xanthomatosis
inborn errors of metabolism
rare disease

Additional relevant MeSH terms:
Xanthomatosis, Cerebrotendinous
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Metabolism, Inborn Errors
Chenodeoxycholic Acid
Anticholesteremic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on September 02, 2015